Insider transactions

EDGAR

enVVeno Medical Corporation

Transactions reported by directors, officers and 10% owners on SEC Forms 3, 4 and 5, read from each filing’s XML. Codes and their wording are the SEC’s own.

A Form 4 is due within two business days of the transaction, so the most recent trades may not be filed yet.

Window: transactions dated on or after 2025-11-19.

Open-market purchases (code P)
0 transactions, — shares
Open-market sales (code S)
4 transactions, 5,191 shares
Sum of shares × price per share: 4,921.586

Totals add the filed transactions listed; they are counts of what was reported, not a measure of direction.

Showing 1–11 of 11

Insider transactions, newest first, as filed on SEC Forms 3, 4 and 5
DateReporting ownerCodeAcquired or disposedSharesPrice per share, as filedValue (derived)Shares owned afterDirect or indirectRule 10b5-1 boxNotesSource
2026-09-11 Filed 2026-09-14Duhay Francis Director
S

Open market or private sale of non-derivative or derivative security

Common Stock
Disposed (D)1111.2100
123.31

Derived: shares × price per share. Exact value 123.3100.

2,351Direct (D) Yes
F1
  • F1 This transaction was completed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in June 2025.
Open filing 0001493152-26-042629 Read from the filing’s XML Dispute this row
2026-06-11 Filed 2026-06-12Duhay Francis Director
S

Open market or private sale of non-derivative or derivative security

Common Stock
Disposed (D)14010.305
1,442.7

Derived: shares × price per share. Exact value 1442.700.

2,362Direct (D) Yes
F1
  • F1 This transaction was completed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in June 2025.
Open filing 0001493152-26-028426 Read from the filing’s XML Dispute this row
2026-03-12 Filed 2026-03-13Duhay Francis Director
S

Open market or private sale of non-derivative or derivative security

Common Stock
Disposed (D)14011.5224
1,613.136

Derived: shares × price per share. Exact value 1613.1360.

2,502Direct (D) Yes
F1, F2
  • F1 This transaction was completed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in June 2025.
  • F2 This transaction was executed in multiple trades during the day at prices ranging from $11.5200 to $11.5450, inclusive. The weighted-average price is reported above. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were completed.
Open filing 0001493152-26-010047 Read from the filing’s XML Dispute this row
2025-12-16 Filed 2025-12-18Alavi Hamed Officer: Chief Technology Officer
J

Other acquisition or disposition (describe transaction)

Derivative security: Restricted Stock Units — underlying Common Stock (50,000) — exercise price 0
Disposed (D)50,0000—0Direct (D) No
F1
  • F1 The restricted stock units were issued to the Reporting Person on November 30, 2021 pursuant to the Issuer's Amended and Restated 2016 Omnibus Incentive Plan and the Restricted Stock Unit Agreement, subject to vesting upon the achievement of specified performance milestones. The applicable milestones were not achieved, and accordingly, the Reporting Person has agreed to voluntarily surrender and cancel the unvested Restricted Stock Units.
Open filing 0001493152-25-028394 Read from the filing’s XML Dispute this row
2025-12-16 Filed 2025-12-18BERMAN ROBERT ANDREW Director · Officer: Chief Executive Officer
J

Other acquisition or disposition (describe transaction)

Derivative security: Restricted Stock Units — underlying Common Stock (200,000) — exercise price 0
Disposed (D)200,0000—0Direct (D) No
F1
  • F1 The restricted stock units were issued to the Reporting Person on November 30, 2021 pursuant to the Issuer's Amended and Restated 2016 Omnibus Incentive Plan and the Restricted Stock Unit Agreement, subject to vesting upon the achievement of specified performance milestones. The applicable milestones were not achieved, and accordingly, the Reporting Person has agreed to voluntarily surrender and cancel the unvested Restricted Stock Units.
Open filing 0001493152-25-028396 Read from the filing’s XML Dispute this row
2025-12-16 Filed 2025-12-18Glickman Marc H. Officer: SVP Chief Medical Officer
J

Other acquisition or disposition (describe transaction)

Derivative security: Restricted Stock Units — underlying Common Stock (100,000) — exercise price 0
Disposed (D)100,0000—0Direct (D) No
F1
  • F1 The restricted stock units were issued to the Reporting Person on November 30, 2021 pursuant to the Issuer's Amended and Restated 2016 Omnibus Incentive Plan and the Restricted Stock Unit Agreement, subject to vesting upon the achievement of specified performance milestones. The applicable milestones were not achieved, and accordingly, the Reporting Person has agreed to voluntarily surrender and cancel the unvested Restricted Stock Units.
Open filing 0001493152-25-028392 Read from the filing’s XML Dispute this row
2025-12-11 Filed 2025-12-15Gray Robert Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Options — underlying Common Stock (135,883) — exercise price 0.325
Acquired (A)135,8830—135,883Direct (D) No
F1
  • F1 The common stock options were issued to the Reporting Person on December 11, 2025 pursuant to the Issuer's Amended and Restated 2016 Omnibus Incentive Plan, as amended . The award is subject to time-based vesting and will vest in equal quarterly installments on the last day of each fiscal quarter during the 2026 calendar year.
Open filing 0001493152-25-027834 Read from the filing’s XML Dispute this row
2025-12-11 Filed 2025-12-15Duhay Francis Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Options — underlying Common Stock (135,883) — exercise price 0.325
Acquired (A)135,8830—135,883Direct (D) No
F1
  • F1 The common stock options were issued to the Reporting Person on December 11, 2025 pursuant to the Issuer's Amended and Restated 2016 Omnibus Incentive Plan, as amended. The award is subject to time-based vesting and will vest in equal quarterly installments on the last day of each fiscal quarter during the 2026 calendar year.
Open filing 0001493152-25-027848 Read from the filing’s XML Dispute this row
2025-12-11 Filed 2025-12-15Jenusaitis Matthew Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Options — underlying Common Stock (135,883) — exercise price 0.325
Acquired (A)135,8830—135,883Direct (D) No
F1
  • F1 The common stock options were issued to the Reporting Person on December 11, 2025 pursuant to the Issuer's Amended and Restated 2016 Omnibus Incentive Plan, as amended. The award is subject to time-based vesting and will vest in equal quarterly installments on the last day of each fiscal quarter during the 2026 calendar year.
Open filing 0001493152-25-027832 Read from the filing’s XML Dispute this row
2025-12-11 Filed 2025-12-15Shrivastava Sanjay Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Options — underlying Common Stock (135,883) — exercise price 0.325
Acquired (A)135,8830—135,883Direct (D) No
F1
  • F1 The common stock options were issued to the Reporting Person on December 11, 2025 pursuant to the Issuer's Amended and Restated 2016 Omnibus Incentive Plan, as amended . The award is subject to time-based vesting and will vest in equal quarterly installments on the last day of each fiscal quarter during the 2026 calendar year.
Open filing 0001493152-25-027826 Read from the filing’s XML Dispute this row
2025-12-11 Filed 2025-12-12Duhay Francis Director
S

Open market or private sale of non-derivative or derivative security

Common Stock
Disposed (D)4,9000.3556
1,742.44

Derived: shares × price per share. Exact value 1742.4400.

92,544Direct (D) Yes
F1, F2
  • F1 This transaction was completed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in June 2025.
  • F2 This transaction was executed in multiple trades during the day at prices ranging from $0.3554 to $0.3573, inclusive. The weighted-average price is reported above. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were completed.
Open filing 0001493152-25-027510 Read from the filing’s XML Dispute this row

Institutional holders (Form 13F)

Quarter ending 2026-09-30: 8,905 filings read, the latest filed 2026-11-18. Prior quarter ending 2026-06-30: 9,170 filings read.

Showing 1–17 of 17

Institutional holders, largest position first, as filed
ManagerShares or principalValue as filedChange from the prior quarterSource
KINGDON CAPITAL MANAGEMENT, L.L.C. Partly reported under another manager36,166 SH282,095 dollarsUnchanged Prior quarter: 36,166Open filing 0001000097-26-000012 Filed 2026-11-16 Dispute this row
CM Management, LLC 17,142 SH133,708 dollarsLower by 18,572 Prior quarter: 35,714Open filing 0001841857-26-000004 Filed 2026-11-12 Dispute this row
CITADEL ADVISORS LLC Partly reported under another manager15,314 SH129,556 dollarsNot in the prior quarter’s filings read Open filing 0001104659-26-128228 Filed 2026-11-16 Dispute this row
VANGUARD CAPITAL MANAGEMENT LLC 6,287 SH53,188 dollarsUnchanged Prior quarter: 6,287Open filing 0002100119-26-001711 Filed 2026-11-13 Dispute this row
JPMORGAN CHASE CO Partly reported under another manager5,219 SH44,048 dollarsHigher by 11 Prior quarter: 5,208Open filing 0000019617-26-000404 Filed 2026-11-12 Dispute this row
VANGUARD FIDUCIARY TRUST CO 2,184 SH18,477 dollarsUnchanged Prior quarter: 2,184Open filing 0000933478-26-000017 Filed 2026-11-13 Dispute this row
UBS Group AG Partly reported under another manager1,965 SH15,327 dollarsHigher by 1,964 Prior quarter: 1Open filing 0001610520-26-000121 Filed 2026-11-10 Dispute this row
Westside Investment Management, Inc. 1,525 SH11,895 dollarsUnchanged Prior quarter: 1,525Open filing 0001538383-26-000005 Filed 2026-11-02 Dispute this row
Tower Research Capital LLC (TRC) Partly reported under another manager580 SH4,524 dollarsHigher by 249 Prior quarter: 331Open filing 0001533421-26-000010 Filed 2026-11-16 Dispute this row
Mirae Asset Global Investments Co., Ltd. 539 SH4,204 dollarsUnchanged Prior quarter: 539Open filing 0000905148-26-004586 Filed 2026-10-29 Dispute this row
BlackRock, Inc. Partly reported under another manager414 SH3,229 dollarsUnchanged Prior quarter: 414Open filing 0002012383-26-003985 Filed 2026-11-13 Dispute this row
Vanguard Global Advisers, LLC 77 SH651 dollarsUnchanged Prior quarter: 77Open filing 0001811242-26-000017 Filed 2026-11-13 Dispute this row
MORGAN STANLEY Partly reported under another manager59 SH460 dollarsUnchanged Prior quarter: 59Open filing 0000895421-26-000309 Filed 2026-11-13 Dispute this row
WELLS FARGO COMPANY/MN Partly reported under another manager57 SH445 dollarsLower by 57 Prior quarter: 114Open filing 0000072971-26-000342 Filed 2026-11-16 Dispute this row
OSAIC HOLDINGS, INC. Partly reported under another manager7 SH60 dollarsUnchanged Prior quarter: 7Open filing 0001677044-26-000011 Filed 2026-11-12 Dispute this row
GROUP ONE TRADING LLC 2 SH17 dollarsUnchanged Prior quarter: 2Open filing 0000932540-26-000017 Filed 2026-11-10 Dispute this row
Caitong International Asset Management Co., Ltd 1 SH8 dollarsNot in the prior quarter’s filings read Open filing 0001628280-26-068135 Filed 2026-10-29 Dispute this row
Managers in the prior quarter with no filing read for the latest

They may simply not have filed yet: absent from the latest quarter’s filings read is not the same as a position sold.

  • Allied Private Wealth LLC 88 SH
  • BARCLAYS PLC 2 SH
  • Form 13F covers long positions in Section 13(f) securities only: no short positions and no securities outside that list.
  • A manager that has not yet filed for the latest quarter is absent, not at zero; filings are due up to 45 days after quarter end.
  • A change is the difference between two quarter-end snapshots, not a trade.
  • A position reported under another manager may also appear in that manager’s filing; rows are not added together.
  • Holdings the securities list cannot place with this company, or places ambiguously, are not shown.

Trades by members of Congress

Periodic transaction reports filed by U.S. House members that name this company’s stock. Dates and amounts are as filed.

No House member’s trade in this company is placed in the store. A trade not yet filed or not linked to a company is absent, not zero.

5% holders (Schedule 13D and 13G)

Schedules filed in the SEC’s structured format (late 2024 onward) are read here. Earlier schedules are free text and are not read.

5% holders, newest event first, as filed
HolderPercent of classShares heldEvent dateFormSource
Thomas A. Satterfield, Jr. Common Stock, $0.00001 par value per share4.833,470.0009/30/2026 Filed 2026-11-10SCHEDULE 13G/AAmendment 1Open filing 0001104659-26-125054 Dispute this row
Braeden Lichti Common Stock, par value $0.00001 per share0.000.0009/11/2026 Filed 2026-09-15SCHEDULE 13D/AAmendment 1Open filing 0001213900-26-100114 Dispute this row
Northstrive Fund II LP Common Stock, par value $0.00001 per share0.000.0009/11/2026 Filed 2026-09-15SCHEDULE 13D/AAmendment 1Open filing 0001213900-26-100114 Dispute this row
Perceptive Advisors LLC Common Stock, $0.00001 par value3.524,60506/30/2026 Filed 2026-08-14SCHEDULE 13G/AAmendment 8Open filing 0001193125-26-352645 Dispute this row
Joseph Edelman Common Stock, $0.00001 par value3.524,60506/30/2026 Filed 2026-08-14SCHEDULE 13G/AAmendment 8Open filing 0001193125-26-352645 Dispute this row
Perceptive Life Sciences Master Fund, Ltd. Common Stock, $0.00001 par value3.524,60506/30/2026 Filed 2026-08-14SCHEDULE 13G/AAmendment 8Open filing 0001193125-26-352645 Dispute this row
Perceptive Advisors LLC Common Stock, $0.00001 par value9.9968,52503/31/2026 Filed 2026-05-15SCHEDULE 13G/AAmendment 7Open filing 0001193125-26-226559 Dispute this row
Joseph Edelman Common Stock, $0.00001 par value9.9968,52503/31/2026 Filed 2026-05-15SCHEDULE 13G/AAmendment 7Open filing 0001193125-26-226559 Dispute this row
Perceptive Life Sciences Master Fund, Ltd. Common Stock, $0.00001 par value9.9968,52503/31/2026 Filed 2026-05-15SCHEDULE 13G/AAmendment 7Open filing 0001193125-26-226559 Dispute this row
Kingdon Capital Management, L.L.C. Common Stock, $0.00001 par value5.536,166.0003/31/2026 Filed 2026-05-15SCHEDULE 13G/AAmendment 1Open filing 0000919574-26-003332 Dispute this row
M. Kingdon Offshore Master Fund, L.P. Common Stock, $0.00001 par value5.536,166.0003/31/2026 Filed 2026-05-15SCHEDULE 13G/AAmendment 1Open filing 0000919574-26-003332 Dispute this row
Kingdon GP, LLC Common Stock, $0.00001 par value5.536,166.0003/31/2026 Filed 2026-05-15SCHEDULE 13G/AAmendment 1Open filing 0000919574-26-003332 Dispute this row
Mark Kingdon Common Stock, $0.00001 par value5.536,166.0003/31/2026 Filed 2026-05-15SCHEDULE 13G/AAmendment 1Open filing 0000919574-26-003332 Dispute this row
Braeden Lichti Common Stock, par value $0.00001 per share5.0533,151.0002/20/2026 Filed 2026-02-20SCHEDULE 13DOpen filing 0001213900-26-018626 Dispute this row
Northstrive Fund II LP Common Stock, par value $0.00001 per share3.0720,129.0002/20/2026 Filed 2026-02-20SCHEDULE 13DOpen filing 0001213900-26-018626 Dispute this row
Northstrive Fund II LP Common Stock, par value $0.00001 per share3.0720,129.0002/20/2026 Filed 2026-02-20SCHEDULE 13DOpen filing 0001213900-26-018625 Dispute this row
Braeden Lichti Common Stock, par value $0.00001 per share5.0533,151.0002/20/2026 Filed 2026-02-20SCHEDULE 13DOpen filing 0001213900-26-018625 Dispute this row
Braeden Lichti Common Stock, $0.00001 par value per share5.0533,151.0002/10/2026 Filed 2026-02-10SCHEDULE 13GOpen filing 0001213900-26-014296 Dispute this row
Northstrive Fund II LP Common Stock, $0.00001 par value per share3.0720,129.0002/10/2026 Filed 2026-02-10SCHEDULE 13GOpen filing 0001213900-26-014296 Dispute this row
Northstrive Fund II LP Common Stock, $0.00001 par value per share3.0720,129.0002/10/2026 Filed 2026-02-10SCHEDULE 13GOpen filing 0001213900-26-014300 Dispute this row
Braeden Lichti Common Stock, $0.00001 par value per share5.0533,151.0002/10/2026 Filed 2026-02-10SCHEDULE 13GOpen filing 0001213900-26-014300 Dispute this row
Perceptive Advisors LLC Common Stock, $0.00001 par value9.992,048,51512/31/2025 Filed 2026-02-17SCHEDULE 13G/AAmendment 6Open filing 0001193125-26-054529 Dispute this row
Joseph Edelman Common Stock, $0.00001 par value9.992,048,51512/31/2025 Filed 2026-02-17SCHEDULE 13G/AAmendment 6Open filing 0001193125-26-054529 Dispute this row
Perceptive Life Sciences Master Fund, Ltd. Common Stock, $0.00001 par value9.992,048,51512/31/2025 Filed 2026-02-17SCHEDULE 13G/AAmendment 6Open filing 0001193125-26-054529 Dispute this row
Thomas A. Satterfield, Jr. Common Stock, $0.00001 par value per share9.01,822,500.0011/14/2025 Filed 2025-11-19SCHEDULE 13GOpen filing 0001104659-25-114096 Dispute this row
Nantahala Capital Management, LLC Common Stock, $0.00001 par value3.46688,940.0009/30/2025 Filed 2025-11-14SCHEDULE 13G/AAmendment 2Open filing 0001104659-25-112662 Dispute this row
Wilmot B. Harkey Common Stock, $0.00001 par value3.46688,940.0009/30/2025 Filed 2025-11-14SCHEDULE 13G/AAmendment 2Open filing 0001104659-25-112662 Dispute this row
Daniel Mack Common Stock, $0.00001 par value3.46688,940.0009/30/2025 Filed 2025-11-14SCHEDULE 13G/AAmendment 2Open filing 0001104659-25-112662 Dispute this row
Kingdon Capital Management, L.L.C. Common Stock, $0.00001 par value7.11,359,261.0009/02/2025 Filed 2025-09-09SCHEDULE 13GOpen filing 0000919574-25-005609 Dispute this row
M. Kingdon Offshore Master Fund, L.P. Common Stock, $0.00001 par value6.61,265,845.0009/02/2025 Filed 2025-09-09SCHEDULE 13GOpen filing 0000919574-25-005609 Dispute this row
Kingdon GP, LLC Common Stock, $0.00001 par value6.61,265,845.0009/02/2025 Filed 2025-09-09SCHEDULE 13GOpen filing 0000919574-25-005609 Dispute this row
Mark Kingdon Common Stock, $0.00001 par value7.11,359,261.0009/02/2025 Filed 2025-09-09SCHEDULE 13GOpen filing 0000919574-25-005609 Dispute this row

Percent is of the class the filing names, as the holder stated it. Members of a group each report the group’s shares, so rows are not added together.

What was read

2,544,215 filings read, dated 2004-06-14 to 2026-11-18: Forms 3, 3/A, 4, 4/A, 5, 5/A.

Years can be incomplete while the archive is still being read. A year with few filings here is not a statement that few were made.

Filings read, by filing year
Filing yearFilings read
201517,857
2016222,642
2017222,009
2018223,345
2019216,482
2020170,508
2021249,835
2022231,682
2023229,674
2024234,045
2025235,520
2026262,403

Filings made before the SEC required XML are listed, not extracted.

Back to enVVeno Medical Corporation